Nicola M. Tomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicola M. Tomas has a total of 399 co-authors. Here are the top co-authors by number of shared publications:
- Tobias Bruno Huber
III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16 shared publications Larissa Seifert
III. Department of Medicine, and
9 shared publicationsSilke Dehde
III. Department of Medicine, University Medical Center Hamburg-Eppendorf; Hamburg, 20246, Germany
9 shared publicationsGunther Zahner
III. Department of Medicine, and
8 shared publications- Friedrich Koch-Nolte
Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6 shared publications Oliver Kretz
III. Department of Medicine, and
6 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (21)
Anti-PLA2R autoantibodies induce complement activation via IgG subclass–dependent epitope pairings in membranous nephropathy
Membranous nephropathy (MN) is an autoimmune kidney disease and a major cause of nephrotic syndrome in adults. Although autoantibodies against phospholipase A2 receptor 1 (PLA2R) and complement activation are central to disease pathogenesis, the mechanisms by which anti-PLA2R antibodies activate complement at the podocyte surface remain incompletely defined. Here, we cloned 14 patient-derived anti-PLA2R mAbs and found that they predominantly recognized the N-terminal cysteine-rich (CysR) and C-type lectin domain 1 (CTLD1) regions of PLA2R. Individual anti-PLA2R mAbs induced little or no complement-dependent cytotoxicity (CDC) of PLA2R-expressing podocytes in vitro. In contrast, paired mAbs targeting distinct epitopes, particularly CysR and CTLD1, markedly enhanced CDC. This effect was strongest for IgG1 and IgG3 antibodies, whereas IgG4 alone did not activate complement but modulated CDC in combination with IgG1. Purified IgG from patients with PLA2R-associated MN similarly induced CDC, which was augmented by addition of anti–PLA2R IgG1 and reduced by anti–PLA2R IgG4 or Fab fragments targeting CysR or CTLD1. In human PLA2R–expressing mice, paired anti-PLA2R antibodies increased glomerular complement deposition and induced albuminuria. These findings identify epitope pairing as a key determinant of complement activation in PLA2R-associated MN and support epitope-specific targeting strategies as a promising avenue for therapeutic intervention.
- 8 September 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (21)
Open AccessAnti-PLA2R autoantibodies induce complement activation via IgG subclass–dependent epitope pairings in membranous nephropathy
Membranous nephropathy (MN) is an autoimmune kidney disease and a major cause of nephrotic syndrome in adults. Although autoantibodies against phospholipase A2 receptor 1 (PLA2R) and complement activation are central to disease pathogenesis, the mechanisms by which anti-PLA2R antibodies activate complement at the podocyte surface remain incompletely defined. Here, we cloned 14 patient-derived anti-PLA2R mAbs and found that they predominantly recognized the N-terminal cysteine-rich (CysR) and C-type lectin domain 1 (CTLD1) regions of PLA2R. Individual anti-PLA2R mAbs induced little or no complement-dependent cytotoxicity (CDC) of PLA2R-expressing podocytes in vitro. In contrast, paired mAbs targeting distinct epitopes, particularly CysR and CTLD1, markedly enhanced CDC. This effect was strongest for IgG1 and IgG3 antibodies, whereas IgG4 alone did not activate complement but modulated CDC in combination with IgG1. Purified IgG from patients with PLA2R-associated MN similarly induced CDC, which was augmented by addition of anti–PLA2R IgG1 and reduced by anti–PLA2R IgG4 or Fab fragments targeting CysR or CTLD1. In human PLA2R–expressing mice, paired anti-PLA2R antibodies increased glomerular complement deposition and induced albuminuria. These findings identify epitope pairing as a key determinant of complement activation in PLA2R-associated MN and support epitope-specific targeting strategies as a promising avenue for therapeutic intervention.
- Open Access
- 17 June 2026
- Published by Springer Nature in Research Square
Diversion of Arginine’s dietary metabolic fate in proteinuric kidney disease
Proteinuria predicts chronic kidney disease progression and cardiometabolic mortality, yet how sustained urinary protein loss reshapes interorgan metabolism remains unclear. Here, we tested whether proteinuric kidney disease alters whole-body amino-acid and nitrogen handling by applying long-term dietary arginine isotope tracing in a proteinuric podocin-mutant mouse model, complemented by ex vivo nephron-segment metabolism and human cohort analyses. Because arginine connects amino acid use in protein synthesis, amino acid catabolism, and the urea cycle, the dietary isotope label allowed us to follow both metabolite flux and protein incorporation across organs over time. Proteinuria did not trigger a broad compensatory increase in protein synthesis. Instead, it caused a kidney-centered rerouting of arginine metabolism. Arginine use shifted away from hepatic ureagenesis and toward renal glutamate-, proline-, and aspartate-linked fate. Across organs, most proteins incorporated recycled arginine, whereas albumin preferentially incorporated diet-derived arginine, identifying albumin as a major non-recycled arginine sink during proteinuric disease. In the kidney, proximal nephron segments showed coordinated remodeling of arginine and proline metabolism in association with tubular albumin handling. This rerouting favored proline synthesis and early collagen incorporation before overt fibrosis was established. Isotope-resolved nitrogen tracing indicated that this renal diversion of arginine occurs at the expense of coordinated nitrogen and acid handling, as reflected by reduced urinary ammonium excretion, tissue accumulation of arginine-derived ammonia, and altered abundance of enzymes involved in ammonium detoxification. In humans, circulating aspartate was elevated during active proteinuric disease and decreased in remission, independently of glomerular filtration rate, and both aspartate and proline associated with histological markers of fibrotic remodeling in biopsies from glomerular disease patients. Consequently, in proteinuric mice, a high dietary content of aspartate/asparagine further aggravated collagen accumulation and fibrosis-related remodeling of high-proline-content proteins, while impairing acid excretion. Together, these findings define proteinuric kidney disease as a chronic interorgan nitrogen-redistribution state that links selective protein turnover, impaired ammonium disposal, acid retention, and a renal profibrotic metabolic environment.
- 17 June 2026
- Published by Springer Nature in Research Square
Open AccessDiversion of Arginine’s dietary metabolic fate in proteinuric kidney disease
Proteinuria predicts chronic kidney disease progression and cardiometabolic mortality, yet how sustained urinary protein loss reshapes interorgan metabolism remains unclear. Here, we tested whether proteinuric kidney disease alters whole-body amino-acid and nitrogen handling by applying long-term dietary arginine isotope tracing in a proteinuric podocin-mutant mouse model, complemented by ex vivo nephron-segment metabolism and human cohort analyses. Because arginine connects amino acid use in protein synthesis, amino acid catabolism, and the urea cycle, the dietary isotope label allowed us to follow both metabolite flux and protein incorporation across organs over time. Proteinuria did not trigger a broad compensatory increase in protein synthesis. Instead, it caused a kidney-centered rerouting of arginine metabolism. Arginine use shifted away from hepatic ureagenesis and toward renal glutamate-, proline-, and aspartate-linked fate. Across organs, most proteins incorporated recycled arginine, whereas albumin preferentially incorporated diet-derived arginine, identifying albumin as a major non-recycled arginine sink during proteinuric disease. In the kidney, proximal nephron segments showed coordinated remodeling of arginine and proline metabolism in association with tubular albumin handling. This rerouting favored proline synthesis and early collagen incorporation before overt fibrosis was established. Isotope-resolved nitrogen tracing indicated that this renal diversion of arginine occurs at the expense of coordinated nitrogen and acid handling, as reflected by reduced urinary ammonium excretion, tissue accumulation of arginine-derived ammonia, and altered abundance of enzymes involved in ammonium detoxification. In humans, circulating aspartate was elevated during active proteinuric disease and decreased in remission, independently of glomerular filtration rate, and both aspartate and proline associated with histological markers of fibrotic remodeling in biopsies from glomerular disease patients. Consequently, in proteinuric mice, a high dietary content of aspartate/asparagine further aggravated collagen accumulation and fibrosis-related remodeling of high-proline-content proteins, while impairing acid excretion. Together, these findings define proteinuric kidney disease as a chronic interorgan nitrogen-redistribution state that links selective protein turnover, impaired ammonium disposal, acid retention, and a renal profibrotic metabolic environment.
- Top Cited PapersOpen Access
- 27 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 548-565
Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- 27 March 2026
- Published by Elsevier in Kidney International
- Vol. 110 (3) , 548-565
Top Cited PapersOpen AccessTargeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Open Access
Cryo-electron tomographic analysis of anti-nephrin–mediated podocytopathy
Nephrotic kidney diseases are characterized by proteinuria caused by dysfunction of the glomerular filtration barrier. Here, we perform an ultrastructural analysis of anti-nephrin–mediated podocytopathy by visualizing the near-native slit diaphragm in situ across defined stages of disease progression using cryo-electron tomography. Our analysis shows that at early disease stages punctuate cell–cell membrane approximations appear, with basal membrane apposition between adjacent podocyte foot processes, while the initially planar, fishnet slit diaphragm progressively bends into a dome-shaped configuration towards the urinary space. At later stages, slit diaphragm disappearance coincides with the appearance of endosomal and vesicular structures and extensive cytoskeletal reorganization. These cryo-electron tomography–based observations provide a structural framework for understanding how antibody binding to nephrin translates into podocyte architectural failure.
Open AccessCryo-electron tomographic analysis of anti-nephrin–mediated podocytopathy
Nephrotic kidney diseases are characterized by proteinuria caused by dysfunction of the glomerular filtration barrier. Here, we perform an ultrastructural analysis of anti-nephrin–mediated podocytopathy by visualizing the near-native slit diaphragm in situ across defined stages of disease progression using cryo-electron tomography. Our analysis shows that at early disease stages punctuate cell–cell membrane approximations appear, with basal membrane apposition between adjacent podocyte foot processes, while the initially planar, fishnet slit diaphragm progressively bends into a dome-shaped configuration towards the urinary space. At later stages, slit diaphragm disappearance coincides with the appearance of endosomal and vesicular structures and extensive cytoskeletal reorganization. These cryo-electron tomography–based observations provide a structural framework for understanding how antibody binding to nephrin translates into podocyte architectural failure.
- Open Access
- 26 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (8)
Functional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy
Although the pathogenic role of autoantibodies targeting the podocyte protein THSD7A in membranous nephropathy (MN) is well described, the consequences of autoantibody binding for podocyte homeostasis and the function of THSD7A remain unclear. Here, we induced an MN model in control and podocyte-specific Thsd7a -KO ( Thsd7a –/– ) mice using rabbit anti-THSD7A antibodies, followed by transcriptome and proteome analyses. Anti-THSD7A antibodies in WT mice caused significant loss of key slit diaphragm (SD) proteins, such as nephrin and NEPH1, without transcriptional downregulation. Glomeruli showed substantial transcriptomic and proteomic reconfiguration indicative of extensive podocyte injury, including disruptions in podocyte adhesion, cytoskeletal dynamics, and marked upregulation of ubiquitin-proteasome system components, cathepsins, and ADAM proteases. Notably, experiments in C3-deficient mice revealed that proteolytic activation and SD protein loss are driven by complement-independent pathways. Thsd7a –/– mice only displayed a mild phenotype under basal conditions, and they were completely protected from MN development upon anti-THSD7A antibody transfer. Finally, interactome analysis identified a protein complex, including THSD7A and integrin α3, linking THSD7A complexes to pathogenic regulation of cytoskeleton, adhesion, and membrane signaling in MN. Thus, anti-THSD7A antibodies induce profound molecular reconfiguration, including dysregulated proteolytic systems via a complement-independent pathway, revealing potential therapeutic targets in MN.
- 26 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (8)
Open AccessFunctional characterization of podocyte-expressed THSD7A in experimental membranous nephropathy
Although the pathogenic role of autoantibodies targeting the podocyte protein THSD7A in membranous nephropathy (MN) is well described, the consequences of autoantibody binding for podocyte homeostasis and the function of THSD7A remain unclear. Here, we induced an MN model in control and podocyte-specific Thsd7a -KO ( Thsd7a –/– ) mice using rabbit anti-THSD7A antibodies, followed by transcriptome and proteome analyses. Anti-THSD7A antibodies in WT mice caused significant loss of key slit diaphragm (SD) proteins, such as nephrin and NEPH1, without transcriptional downregulation. Glomeruli showed substantial transcriptomic and proteomic reconfiguration indicative of extensive podocyte injury, including disruptions in podocyte adhesion, cytoskeletal dynamics, and marked upregulation of ubiquitin-proteasome system components, cathepsins, and ADAM proteases. Notably, experiments in C3-deficient mice revealed that proteolytic activation and SD protein loss are driven by complement-independent pathways. Thsd7a –/– mice only displayed a mild phenotype under basal conditions, and they were completely protected from MN development upon anti-THSD7A antibody transfer. Finally, interactome analysis identified a protein complex, including THSD7A and integrin α3, linking THSD7A complexes to pathogenic regulation of cytoskeleton, adhesion, and membrane signaling in MN. Thus, anti-THSD7A antibodies induce profound molecular reconfiguration, including dysregulated proteolytic systems via a complement-independent pathway, revealing potential therapeutic targets in MN.
- Open Access
- 23 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (4)
Structural modeling and functional characterization of a novel gain-of-function TLR8 variant causing severe inflammatory syndrome
With the increasing use of genetic sequencing to investigate inborn errors of immunity, rare variants are frequently identified, yet their clinical relevance often remains uncertain. Establishing pathogenicity requires a multidisciplinary approach that integrates genetic, structural, functional, and clinical data. Here, we used such a strategy to investigate a previously unreported hemizygous missense variant — alanine (A) to threonine (T) at residue 518 — in Toll-like receptor 8 (TLR8), identified in 2 male siblings with recurrent infections and systemic inflammation, characterized by a proinflammatory immune signature and B cell dysregulation. Functional studies showed that the TLR8 A518T variant enhanced NF-κB activation and increased secretion of proinflammatory cytokines compared with WT TLR8 upon stimulation, consistent with a gain-of-function effect. Protein degradation and turnover assays revealed reduced abundance of the mutant TLR8 protein due to faster turnover and increased proteasomal degradation. Computational modeling predicted enhanced structural stabilization of the active TLR8 homodimer interface via additional water-mediated hydrogen bonds introduced by the A518T substitution. Together, these findings integrating structural modeling with functional assays identify a novel TLR8 ligand-specific gain-of-function mutation resulting in complex immunopathology in 2 siblings.
- 23 February 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (4)
Open AccessStructural modeling and functional characterization of a novel gain-of-function TLR8 variant causing severe inflammatory syndrome
With the increasing use of genetic sequencing to investigate inborn errors of immunity, rare variants are frequently identified, yet their clinical relevance often remains uncertain. Establishing pathogenicity requires a multidisciplinary approach that integrates genetic, structural, functional, and clinical data. Here, we used such a strategy to investigate a previously unreported hemizygous missense variant — alanine (A) to threonine (T) at residue 518 — in Toll-like receptor 8 (TLR8), identified in 2 male siblings with recurrent infections and systemic inflammation, characterized by a proinflammatory immune signature and B cell dysregulation. Functional studies showed that the TLR8 A518T variant enhanced NF-κB activation and increased secretion of proinflammatory cytokines compared with WT TLR8 upon stimulation, consistent with a gain-of-function effect. Protein degradation and turnover assays revealed reduced abundance of the mutant TLR8 protein due to faster turnover and increased proteasomal degradation. Computational modeling predicted enhanced structural stabilization of the active TLR8 homodimer interface via additional water-mediated hydrogen bonds introduced by the A518T substitution. Together, these findings integrating structural modeling with functional assays identify a novel TLR8 ligand-specific gain-of-function mutation resulting in complex immunopathology in 2 siblings.
- Open Access
Novel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells
Background: IgE‐associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations. Methods: In this study, we developed and evaluated a bispecific T‐cell engager (TCE) and a half‐life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE‐producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE‐NKCE constructs were designed to target the CεmX domain of membrane‐bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase‐based cytotoxicity assays using Ramos and U266 B‐cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK‐cell line NK‐92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry. Results: Both TCE and HLE‐NKCE specifically mediated killing of CεmX‐expressing cells in a dose‐ and effector‐to‐target (E:T) ratio‐dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE‐NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T‐ and NK‐cell activation was observed only in the presence of target cells and TCE. Conclusion: Our novel anti‐CεmX TCE and HLE‐NKCE effectively target and eliminate mIgE‐expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off‐the‐shelf therapeutics for the treatment of IgE‐associated allergic diseases.
Open AccessNovel Bispecific Engagers Targeting the CεmX Domain of mIgE ‐Expressing Cells
Background: IgE‐associated allergic diseases, affecting approximately 30% of the global population, are a major health burden. Standard treatments, including pharmacotherapy and allergen immunotherapy (AIT), have limitations such as adverse effects, insufficient symptom relief and long treatment durations. Methods: In this study, we developed and evaluated a bispecific T‐cell engager (TCE) and a half‐life extended (HLE) bispecific natural killer (NK) cell engager (NKCE) targeting IgE‐producing cells, to offer novel, potentially curative therapeutic options. The TCE and HLE‐NKCE constructs were designed to target the CεmX domain of membrane‐bound IgE (mIgE) and engage T cells and NK cells, respectively. Their efficacy was assessed through in vitro luciferase‐based cytotoxicity assays using Ramos and U266 B‐cell lines expressing mIgE as target cells, and primary human immune effector cells and the NK‐cell line NK‐92 as effector cells. Additional characterisation of the constructs was performed using flow cytometry. Results: Both TCE and HLE‐NKCE specifically mediated killing of CεmX‐expressing cells in a dose‐ and effector‐to‐target (E:T) ratio‐dependent manner. The TCE demonstrated robust activity even at low antigen densities and concentrations as low as 1 ng/mL (18 pM). The HLE‐NKCE effectively mediated killing in the presence of human serum albumin, suggesting functionality in physiological conditions. T‐ and NK‐cell activation was observed only in the presence of target cells and TCE. Conclusion: Our novel anti‐CεmX TCE and HLE‐NKCE effectively target and eliminate mIgE‐expressing cells in vitro. Although further investigation is needed, our bispecific engagers are promising off‐the‐shelf therapeutics for the treatment of IgE‐associated allergic diseases.
- Top Cited PapersOpen Access
- 23 January 2026
- Published by Elsevier in Kidney International Reports
- Vol. 11 (4) , 103794
Effect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease
- 23 January 2026
- Published by Elsevier in Kidney International Reports
- Vol. 11 (4) , 103794
Top Cited PapersOpen AccessEffect of Steroids on Anti-nephrin Autoantibodies and B cells in Minimal Change Disease
- 6 January 2026
- Published by Elsevier in Kidney International
- Vol. 109 (1) , 31-33
Toward precision immunotherapy in nephrology: 1 step forward
- 6 January 2026
- Published by Elsevier in Kidney International
- Vol. 109 (1) , 31-33
Toward precision immunotherapy in nephrology: 1 step forward
- Open Access
- 30 September 2025
- Published by Elsevier in Kidney International
- Vol. 108 (6) , 1179-1183
Patient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice
- 30 September 2025
- Published by Elsevier in Kidney International
- Vol. 108 (6) , 1179-1183
Open AccessPatient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice